Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 20;60(39):21558-21564.
doi: 10.1002/anie.202109062. Epub 2021 Aug 20.

A Nonheme Mononuclear {FeNO}7 Complex that Produces N2 O in the Absence of an Exogenous Reductant

Affiliations

A Nonheme Mononuclear {FeNO}7 Complex that Produces N2 O in the Absence of an Exogenous Reductant

Aniruddha Dey et al. Angew Chem Int Ed Engl. .

Abstract

A new nonheme iron(II) complex, FeII (Me3 TACN)((OSiPh2 )2 O) (1), is reported. Reaction of 1 with NO(g) gives a stable mononitrosyl complex Fe(NO)(Me3 TACN)((OSiPh2 )2 O) (2), which was characterized by Mössbauer (δ=0.52 mm s-1 , |ΔEQ |=0.80 mm s-1 ), EPR (S=3/2), resonance Raman (RR) and Fe K-edge X-ray absorption spectroscopies. The data show that 2 is an {FeNO}7 complex with an S=3/2 spin ground state. The RR spectrum (λexc =458 nm) of 2 combined with isotopic labeling (15 N, 18 O) reveals ν(N-O)=1680 cm-1 , which is highly activated, and is a nearly identical match to that seen for the reactive mononitrosyl intermediate in the nonheme iron enzyme FDPnor (ν(NO)=1681 cm-1 ). Complex 2 reacts rapidly with H2 O in THF to produce the N-N coupled product N2 O, providing the first example of a mononuclear nonheme iron complex that is capable of converting NO to N2 O in the absence of an exogenous reductant.

Keywords: iron; nitric oxide; nitrous oxide; nonheme; reduction.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Plausible mechanisms for N2O formation by FDPnor.
Scheme 1.
Scheme 1.
Syntheses of Complexes 1 and 2
Figure 2.
Figure 2.
(Left) Displacement ellipsoid plot (50% probability level) for 1 at 110(2) K. H atoms are omitted for clarity. Selected bond distances (Å): Fe1–O1, 1.9402(16), Fe1–O2, 1.9458(13), Fe1–N1, 2.265(6), Fe1–N2, 2.280(6), Fe1–N3, 2.212(6). (Top-right) Mössbauer spectrum of 57Fe-1 (80 K). Data: black circles; best fit: red line.
Figure 3.
Figure 3.
UV-vis spectra for 1 (1.4 mM) (black line) after addition of NO(g) to form 2 (green line) in THF. Inset: EPR spectrum of 2 in 2-MeTHF recorded at 8 K, 9.21 GHz.
Figure 4.
Figure 4.
57Fe Mössbauer spectrum (80 K in frozen THF) of 2. Experimental data are plotted as black dots and best fits are overlaid as solid lines. The major species (δ = 0.52 mm s−1, |ΔEQ| = 0.80 mm s−1, 90 %) is shown as a green line. A second broad sub-component with δ = 0.6 mm s−1, |ΔEQ|= 1.00 mm s−1, ГR= ГL = 6.0 (blue line) was added to represent the intermediate relaxation of the doublet at 80 K.
Figure 5.
Figure 5.
Low-temperature RR spectra of 2-NO (black), 2-15NO (red), and 2-15N18O (blue) in THF obtained with a 458-nm laser excitation. The difference spectra are shown in green.
Figure 6.
Figure 6.
Fe K-edge X-ray absorption near edge (XANES) spectra of [FeII(Me3TACN)((OSiPh2)2O)] (1, black line) and [Fe(NO)(Me3TACN)((OSiPh2)2O)] (2, red line).
Figure 7.
Figure 7.
TD-DFT simulated UV-vis absorption spectrum for 2 (dashed purple line) overlaid with the experimental spectrum (red line). The computed spectral excitations are shown as black sticks. Electron difference density map for the computed transition (λmax = 447 nm) is shown with the green and red regions indicating gain and loss of electron density respectively.
Scheme 2.
Scheme 2.
N2O formation from 2.

References

    1. Wasser IM, de Vries S, Moënne-Locco P, Schröder I, Karlin KD, Chem. Rev. 2002, 102, 1201–1234; - PubMed
    2. Szaciłowski K, Chmura A, Stasicka Z, Coord. Chem. Rev. 2005, 249, 2408–2436;
    3. Tennyson AG, Lippard SJ, Chem. Biol. 2011, 18, 1211–1220; - PubMed
    4. Khatua S, Majumdar A, J. Inorg. Biochem. 2015, 142, 145–153; - PubMed
    5. Timmons AJ, Symes MD, Chem. Soc. Rev. 2015, 44, 6708–6722; - PubMed
    6. Wright AM, Hayton TW, Inorg. Chem. 2015, 54, 9330–9341; - PubMed
    7. Romão CV, Vicente JB, Borges PT, Frazão C, Teixeira M, J. Biol. Inorg. Chem. 2016, 21, 39–52; - PubMed
    8. Ferousi C, Majer SH, DiMucci IM, Lancaster KM, Chem. Rev. 2020, 120, 5252–5307. - PMC - PubMed
    1. Kurtz JDM, Dalton Trans. 2007, 4115–4121;
    2. Weitz AC, Giri N, Caranto JD, Kurtz DM, Bominaar EL, Hendrich MP, J. Am. Chem. Soc. 2017, 139, 12009–12019. - PMC - PubMed
    1. Arikawa Y, Onishi M, Coord. Chem. Rev. 2012, 256, 468–478.
    1. Enemark JH, Feltham RD, Coord. Chem. Rev. 1974, 13, 339–406.
    1. Hayashi T, Caranto JD, Wampler DA, Kurtz DM, Moënne-Loccoz P, Biochemistry 2010, 49, 7040–7049; - PMC - PubMed
    2. Caranto JD, Weitz A, Giri N, Hendrich MP, Kurtz DM, Biochemistry 2014, 53, 5631–5637. - PMC - PubMed

Publication types

MeSH terms